Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evogene ( (EVGN) ) has provided an update.
On April 2, 2026, Evogene disclosed it had received a notification from Nasdaq that its ordinary shares failed to meet the exchange’s minimum bid price requirement of $1.00 for 30 consecutive business days. The notice triggers an initial 180-day cure period, running until September 28, 2026, during which Evogene must achieve a closing bid price of at least $1.00 for 10 consecutive business days to regain compliance and avoid potential delisting.
If Evogene does not regain compliance by the end of this first period, it may qualify for an additional 180 days, provided it meets other Nasdaq Capital Market listing standards and commits in writing to address the deficiency. The company said maintaining its Nasdaq listing is a key priority and indicated it may consider measures such as a reverse stock split if the share price does not recover, while stressing that the notice has no immediate impact on trading of its shares on Nasdaq or on its separate listing on the Tel Aviv Stock Exchange.
The most recent analyst rating on (EVGN) stock is a Sell with a $0.82 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, heavy cash burn, negative equity, and declining revenue). Technicals also reflect a downtrend with negative momentum. The earnings call provides partial support through sustained cost cuts and near-term liquidity actions, but top-line weakness and one-time items keep overall risk elevated.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd., dual-listed on Nasdaq and the Tel Aviv Stock Exchange under the symbol EVGN, is a computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries. Its core ChemPass AI platform uses generative AI and experimental validation to discover novel, highly potent small-molecule candidates optimized across multiple development parameters.
Average Trading Volume: 478,886
Technical Sentiment Signal: Sell
Current Market Cap: $7.05M
For an in-depth examination of EVGN stock, go to TipRanks’ Overview page.